Form 4: Zevra Therapeutics Director Corey Michael Watton Awarded Stock Options
SEC Form 4 Filing
Director Corey Michael Watton received stock options for 39,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89, as compensation for board service.
Summary
- Corey Michael Watton, a director of Zevra Therapeutics, Inc., was granted stock options to purchase 39,200 shares of the company's common stock on May 13, 2024.
- The exercise price of the options is $4.89 per share, which is equal to the closing price of Zevra's common stock on the Nasdaq Global Select Market on the grant date.
- The options were awarded as compensation for Watton's service on the company's board of directors, according to the ninth amended and restated non-employee director compensation policy.
- The options vest on the earlier of (i) the first anniversary of the grant date, (ii) one day prior to the first annual meeting of stockholders following the grant date, or (iii) immediately prior to a change in control of the Issuer, subject to continued service on the vesting date.
- The options expire on May 12, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, indicating a stable and ongoing relationship between the director and the company. It's a neutral event with a slightly positive implication for corporate governance.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The vesting schedule incentivizes continued service on the board.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Granting stock options to board members is a common practice to align their interests with the long-term success of the company and its shareholders. This is a standard form 4 filing related to director compensation.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the director to contribute to the company's success.
- The director benefits from the potential future value of the stock options.
Key Dates
| Date | Description |
|---|---|
| 05/13/2024 | Date of the stock option grant. |
| 05/13/2024 | Date of earliest transaction. |
| 05/12/2034 | Expiration date of the stock options. |
| 05/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.